HIV, syphilis, and viral hepatitis among Latin American indigenous peoples and Afro-descendants: a systematic review

Nancy K. Russell,1 Kevin Nazar,2 Sandra del Pino,3 Monica Alonso Gonzalez,3 Ximena P. Díaz Bermúdez,4 and Giovanni Ravasi3

Suggested citation

ABSTRACT
Objective. To identify and summarize existing literature on the burden of HIV, sexually transmitted infections (STIs), and viral hepatitis (VH) in indigenous peoples and Afro-descendants in Latin America to provide a broad panorama of the quantitative data available and highlight problematic data gaps.

Methods. Published and grey literature were systematically reviewed to identify documents published in English, Spanish, or Portuguese with data collected between January 2000 and April 2016 on HIV, STI, and VH disease burden among indigenous peoples and Afro-descendants in 17 Latin American countries.

Results. Sixty-two documents from 12 countries were found. HIV prevalence was generally low (< 1%) but pockets of high prevalence (> 5%) were noted in some indigenous communities in Venezuela (Warao) (9.6%), Peru (Chayahuita) (7.5%), and Colombia (Wayuu females) (7.0%). High active syphilis prevalence (> 5%) was seen in some indigenous communities in Paraguay (11.6% and 9.7%) and Peru (Chayahuita) (6.3%). High endemicity (> 8%) of hepatitis B was found in some indigenous peoples in Mexico (Huichol) (9.4%) and Venezuela (Yanomami: 14.3%; Japregra: 29.5%) and among Afro-descendant quilombola populations in Brazil (Frechal: 12.5%; Farnas do Dionissio: 8.4% in 2008, 9.2% in 2003).

Conclusions. The gaps in existing data on the burden of HIV, STIs, and VH in indigenous peoples and Afro-descendants in Latin America highlight the need to 1) improve national surveillance, by systematically collecting and analyzing ethnicity variables, and implementing integrated biobehavioral studies using robust methodologies and culturally sensitive strategies; 2) develop a region-wide response policy that considers the needs of indigenous peoples and Afro-descendants; and 3) implement an intercultural approach to health and service delivery to eliminate health access barriers and improve health outcomes for these populations.

Keywords
HIV; sexually transmitted diseases; syphilis; hepatitis, viral, human; health of indigenous peoples; Latin America.

1 Consultant, Pan American Health Organization, Washington, D.C., United States of America. Send correspondence to: Nancy K. Russell, nc3russell@yahoo.com
2 George Mason University, Fairfax, VA, United States of America.
4 Public Health Department, University of Brasilia, Brasilia, D.F., Brazil.
Disparities in socioeconomic and health indicators have been reported for indigenous peoples and Afro-descendants in Latin America compared to available benchmarks (1). Concerns have been raised about the vulnerability of these populations to HIV, sexually transmitted infections (STIs), and viral hepatitis (VH). In response, the United Nations (UN) General Assembly made a formal commitment to eliminate barriers to HIV services, including stigma and discrimination in health care settings, and ensure engagement of indigenous communities (2).

Few countries collect disease surveillance data disaggregated by ethnicity, and previous literature reviews on this topic recognized that data on HIV, STIs, and VH in indigenous peoples and Afro-descendants are limited (3–5). In fact, although HIV, STIs, and VH are responsible for a significant burden of disease in Latin America (6–9), little is known about the burden of these infections among the nearly 50 million indigenous peoples (10) and over 110 million Afro-descendants (11) that reside there. The paucity of quantitative and qualitative data remains a barrier to understanding their health situation and the underlying health determinants.

The socioeconomic and health access disadvantages experienced by indigenous peoples and Afro-descendants stem from many factors, including geographic isolation and discrimination (12–14). In addition, economic disparities resulting from globalization have increased migration, amplifying the exposure of these communities to new infections (15, 16). Some advancements in establishing land rights and access to adequate health care for indigenous peoples have occurred (17), but not all Latin American governments have ratified these treaties (18–20).

The UN Agenda for Sustainable Development and the World Health Organization (WHO) Global Health Sector Strategies (2016–2021) for HIV, STIs, and VH (20–23) commit to ending these epidemics as public health threats by 2030. To that end, it is critical that the potential vulnerabilities of indigenous peoples and Afro-descendants in Latin America be further assessed. More complete information on the burden of disease of HIV, STIs, and VH in these populations is needed for evidence-based decisions and the development of an effective regional response. This systematic review aimed to identify and summarize existing literature on the burden of HIV, STIs, and VH in indigenous peoples and Afro-descendants in Latin America to provide a broader panorama of the quantitative data available and highlight problematic data gaps.

MATERIALS AND METHODS

Information sources and search strategy

This systematic review was conducted according to the PRISMA guidelines (24). The search involved both electronic and manual strategies. Documents containing disease burden data on HIV, STIs, and VH from original prevalence studies or national surveillance case-based reporting systems were included. The populations under study were indigenous peoples and Afro-descendants in 17 Latin American countries (Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Uruguay, and Venezuela). Review criteria for indigenous status were widely interpreted and included the following: self-identified, provider-identified, indigenous language spoken in the home, and/or majority (>50%) of a rural population.

Documents published in English, Spanish, or Portuguese with data collected between 1 January 2000 and 15 April 2016 were reviewed for inclusion. The following databases were systematically searched: PubMed (Medline), SciELO (Scientific Library Online), and LILACS (Latin American and Caribbean Center on Health Sciences Information). The following terms were cross-referenced: 1) acquired immune deficiency syndrome, HIV, sexually transmitted diseases, STI, syphilis, or viral hepatitis; 2) indigenous, native, ethnic distribution, Amerindian, Afro-descendant, Afro-Brazilian, or Afro-Colombian; and 3) Latin America, South America, Central America or <name of specific country>. The manual search methodology included: 1) bibliography of review articles and theses found in the automated search; 2) abstracts from International AIDS Society (IAS) conferences5 and other international conferences on HIV, STIs, and VH among indigenous peoples and Afro-descendants; 3) databases from health ministries and institutes; 4) contact with indigenous peoples and Afro-descendant organizations to obtain health indicator reports and studies; 5) contact with UN and other international cooperation agencies involved with health of indigenous and Afro-descendant peoples in search of documents in their databases; 6) documents related to indigenous peoples and HIV in the UN Permanent Forum on Indigenous Issues, the UN Special Rapporteur on the rights of indigenous peoples, and the UN Expert Mechanism on the Rights of Indigenous Peoples. The automated search identified 181 documents and the manual search identified 307 documents (137 from grey literature, 62 from bibliographical review, and 108 from IAS abstracts). The selection process is shown in Figure 1.

Data extraction

The information extracted included author, title, publication name, publication type, date of publication, location of study, population characteristics (including sex and age), name of ethnic group(s), sample size, date of data collection, objective of study, sampling methods, disease burden (numerator and denominator for prevalence), disease screening method, limitations, and findings and recommendations. Document review and disease burden data extraction were performed by two researchers (NKR and KN). Concordance was achieved on 94% of values and all discrepancies were checked with original documents and resolved. Meta-analysis was not considered due to heterogeneity of methods, variation in years of data collection, and differing social/cultural contexts across populations.

RESULTS

A total of 62 documents (64 records) were identified by the systematic review. One document was published in 2017 with data previously obtained via personal communication with the authors (16). About one-third (20 documents) came from Brazil, with Peru and Colombia accounting for another one-fourth (25.8%). No documents were identified from Costa Rica, Ecuador, El Salvador, Nicaragua, or Uruguay. More than half (34 documents) were journal articles, 14 were government reports, eight were...

No. of records identified in automated search: 181
- 89 from PubMed
- 44 from LILACS
- 48 from SciELO

No. of records identified in manual search: 207
- 137 from grey literature
- 108 IAS abstracts
- 62 bibliographic reviews

Total no. of records identified through automated and manual search: 488
No. of records after duplicates (54) removed: 434

No. of records screened: 434
No. of records after those with content not relevant to study objective (110) were excluded: 324
No. of records with full-text document not available: 16

No. of full-text documents obtained and reviewed for eligibility: 308
No. of documents included in review: 62, including two that were sub-divided, adding two additional records, for a total of 64 records

Total sample for the review: n = 64

Source: Prepared by the authors based on the study results.

a IAS: International AIDS Society.
b Including 118 KAP (knowledge, attitude, and practices) and prevention documents not screened out earlier due to broader research objective at outset of review.

published abstracts, and six were other types of documents.

A total of 46 (74%) of the documents reported disease prevalence data from original studies, with the rest (16) reporting case report data. Documents that reported prevalence data from the same study sample were merged into a single record, resulting in 39 unique prevalence studies.

Burden of HIV in indigenous peoples and Afro-descendants

HIV prevalence data were available from 17 studies, including 15 conducted with indigenous peoples and two with Afro-descendants (Garifuna, Honduras) (16, 25–40). Figure 2 shows HIV prevalence data from these 17 studies compared to UNAIDS estimates for the general population (41). Prevalence ranged from zero to 9.6%. Using WHO definitions for concentrated epidemics (42), the prevalence of HIV tended to be low (<1%), yet pockets of high prevalence (>5%) were noted among Warao communities in Venezuela (9.6%) (40), one Chayahuita community in Peru (7.5%) (38), and Wayuu females in Colombia (7.0%) (26). The high prevalence detected among Chayahuita appeared to be isolated to one peri-urban village, as follow-up investigations found relatively low prevalence in other Chayahuita villages (35, 39). Moderately high prevalence rates (1%–5%) were noted in the Garifuna of Honduras (4.5% in 2006 (30, 43–45) and 3.7% in 2012 (29, 46)).

Eleven studies presented HIV prevalence data by sex. The HIV epidemics detected among the Warao (Venezuela) (40) and the Chayahuita (Peru) (38) appear to be more concentrated in males, though only the finding in Venezuela was significant (odds ratio (OR): 7.13; P < 0.001). Among the Garifuna (Honduras), HIV prevalence seemed slightly higher in females, especially in the 2014 study when rural males (1.6%) were compared to rural females (4.9%), yet this difference was not significant (29).

The review also identified 14 documents with HIV/AIDS case reporting or associated mortality data among indigenous peoples and Afro-descendants from six countries (47–60). Data from 10 of 11 documents reporting HIV/AIDS surveillance data are presented in Table 1. In most cases, the data were reported as raw numbers and “percent of all HIV/AIDS cases,” and these percentages were compared to official census data for each ethnic group within their respective countries (10, 61). One document provided case reporting data on indigenous peoples from the Mato Grosso do Sul region of Brazil without providing the total number of cases for that region; these data were left out of the table (60). The only ethnic group found to be overrepresented in terms of HIV/AIDS cases was the Kuna Yala in Panama, who presented an HIV infection rate nearly double that of the general population (234.9/100 000 versus 130.8/100 000 respectively) (56).

In the three documents reporting mortality data (57–59), only two had notable findings. A report from Panama suggested the Ngäbe Buglé peoples are overrepresented in terms of HIV/AIDS-associated deaths (accounting for 4.9% of the population and 7.2% of HIV/AIDS-associated deaths) (59). A study from Chile reported an adjusted mortality rate attributed to HIV of 10.8/100 000 among the Aymara (in Arica and Parinacota) compared to 4.2/100 000 among non-Aymara between 2004 and 2006 (57). This rate rose to 11.2/100 000 from 2007 to 2009 (compared to 4.1 among non-Aymara).

Vulnerable groups. The availability of data on the burden of HIV/AIDS in pregnant indigenous and Afro-descendant women in Latin America was very limited, and evidence of a low burden (<1% prevalence) was observed in two prevalence studies from Brazil (0.07%) and Peru (0.16%) (16, 36). Case reporting data from Brazil also indicated that pregnant indigenous women with HIV represent 0.3% of cases, comparable to the 0.5% that indigenous people account for in Brazil’s population (51). Data on the burden of HIV among indigenous and Afro-descendant youth and children were limited to three documents. The data from one of the documents, a report from...
Data from 17 studies on HIV prevalence in indigenous peoples and Afro-descendants (Latin America, 2007–2017)

<table>
<thead>
<tr>
<th>Region</th>
<th>Indigenous Population</th>
<th>HIV Prevalence in Indigenous Peoples or Afro-descendants (%)</th>
<th>HIV Prevalence in General Population (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brazil</td>
<td>Indigenous peoples</td>
<td>0.1</td>
<td>0.5</td>
</tr>
<tr>
<td>Brazil</td>
<td>Indigenous peoples</td>
<td>0.2</td>
<td>0.4</td>
</tr>
<tr>
<td>Colombia</td>
<td>Wayuu females</td>
<td>0.4</td>
<td>0.7</td>
</tr>
<tr>
<td>Colombia</td>
<td>Embera Chami</td>
<td>0.4</td>
<td>0.7</td>
</tr>
<tr>
<td>Guatemala</td>
<td>Rural females</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Honduras</td>
<td>Garifuna</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>Honduras</td>
<td>Garifuna</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>Mexico</td>
<td>Urban indigenous peoples</td>
<td>0.6</td>
<td>0.6</td>
</tr>
<tr>
<td>Mexico</td>
<td>Mixtecs males</td>
<td>0.0</td>
<td>0.2</td>
</tr>
<tr>
<td>Paraguay</td>
<td>5 indigenous groups</td>
<td>0.8</td>
<td>0.4</td>
</tr>
<tr>
<td>Paraguay</td>
<td>13 indigenous groups</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>Peru</td>
<td>Chayahuita</td>
<td>0.3</td>
<td>0.4</td>
</tr>
<tr>
<td>Peru</td>
<td>6 indigenous groups</td>
<td>0.2</td>
<td>0.4</td>
</tr>
<tr>
<td>Peru</td>
<td>10 indigenous groups</td>
<td>0.3</td>
<td>0.4</td>
</tr>
<tr>
<td>Peru</td>
<td>Chayahuita</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>Peru</td>
<td>Chayahuita</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>Venezuela</td>
<td>Warao</td>
<td>0.5</td>
<td>0.5</td>
</tr>
</tbody>
</table>

> 5% = High prevalence

**Source:** Prepared by the authors based on the study results and published data.

- **UHADS HIV prevalence data closest in year/sex/age:**
- **Non-probability sampling methods used:**
- **Probability sampling methods used:**
- **Indigenous people made up 52% of the study population:**
- **Pregnant women and their current sexual partner:**
- **Based on WHO threshold:**

**Vulnerable groups.** The review identified six documents (four unique studies (16, 36, 62, 66)) containing data on the burden of syphilis in pregnant indigenous women from Bolivia, Brazil, and Peru. One of the two studies in Brazil took place in nine Special Indigenous Health Districts (41, 44) in the Amazon area with treponemal seroprevalence averaging 1.52% (range: 0% in Médio Purus and Parintins to 3.38% in Vale do Javari) (16). The other, a national, hospital-based study among postpartum women (40), found a lower percentage of indigenous women infected (0.55%) versus the general population (1.02%), but this difference was not significant, and a broad definition of syphilis diagnosis was used (66). The study in Bolivia detected a treponemal seroprevalence of 7% in 2004–2005 in a large convenience sampling clinic-based study of pregnant women (41) who spoke only indigenous language, or Spanish and some indigenous language (62). The 2012 study in the Peruvian Amazon was another large convenience sample (41, 248) that covered pregnant indigenous women and found 1.6% prevalence of active syphilis (36).

**Burden of syphilis in indigenous peoples and Afro-descendants**

Data on the burden of STIs (other than HIV) were available from 26 documents from eight countries. All but one of the 26 documents on STIs reported data on syphilis; only nine included data on other STIs. Given the preponderance of syphilis data, this review focused on the burden of syphilis. Three documents contained case reporting and 22 had prevalence data from 16 unique studies (two studies in Afro-descendants and the rest in indigenous groups). Of these 16 studies, eight used non-treponemal tests combined with confirmatory treponemal tests to establish active infection (range: 0.5%–11.6%) (29–30, 33–36, 38, 39); four used treponemal rapid tests exclusively to determine the seroprevalence of syphilis (range: 1.6%–7.0%) (16, 27, 62, 63); one study used a non-treponemal test exclusively (64); and three studies did not report their testing method (28, 31, 37). Figure 3 compares the data from the eight studies on active syphilis with national benchmarks (65), showing higher syphilis prevalence in indigenous peoples and Afro-descendants in all eight studies. Using WHO’s threshold of 5% of active syphilis for identifying high prevalence settings (42), two studies of indigenous groups in Paraguay (33, 34) suggested the existence of high prevalence of active syphilis. One study of a peri-urban Chayahuita village in Peru (38) also found high prevalence of active syphilis, but the two follow-up studies conducted with Chayahuita (in more remote villages, and with larger sample sizes) did not confirm this finding, suggesting the high prevalence detected was limited to the one village (35, 39).
TABLE 1. Data from HIV case reporting in indigenous peoples and Afro-descendants, Latin America, 2005–2015

<table>
<thead>
<tr>
<th>Geographic area (reference)</th>
<th>Ethnic origin of population</th>
<th>Country prevalence (%) of given ethnic origina</th>
<th>No. of HIV cases (% of total reported cases)</th>
<th>Year(s) of data collection</th>
<th>Type of data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bolivia (47)</td>
<td>Ararona, Aymara</td>
<td>41</td>
<td>550 (21.6)</td>
<td>2012</td>
<td>CRVIR HIV/AIDS surveillance (n = 2 544 cases)</td>
</tr>
<tr>
<td>El Alto, Bolivia (48)</td>
<td>Aymara, Quechua</td>
<td>41</td>
<td>53 (38)</td>
<td>2012</td>
<td>CRVIR HIV/AIDS surveillance (n = 139 cases)</td>
</tr>
<tr>
<td>Brazil (49)</td>
<td>Indigenous</td>
<td>0.5</td>
<td>100 (0.3)</td>
<td>Until 2003 (cumulative)</td>
<td>National AIDS surveillance</td>
</tr>
<tr>
<td>Brazil (50)</td>
<td>Indigenous</td>
<td>0.5</td>
<td>53 (0.29)</td>
<td>2009</td>
<td>National AIDS surveillance</td>
</tr>
<tr>
<td>Brazil (51)</td>
<td>Indigenous</td>
<td>0.5</td>
<td>58 (0.26)</td>
<td>2014</td>
<td>National AIDS surveillance</td>
</tr>
<tr>
<td>Brazil (51)</td>
<td>Indigenous</td>
<td>0.5</td>
<td>65 (0.3)</td>
<td>2014</td>
<td>National HIV surveillance</td>
</tr>
<tr>
<td>Colombia (52)</td>
<td>Indigenous</td>
<td>3.4</td>
<td>81 (1.1)</td>
<td>2010</td>
<td>National HIV surveillance data (n = 7 490 cases)</td>
</tr>
<tr>
<td>Guatemala (53, 54)</td>
<td>Maya, Garifuna, Xinca</td>
<td>10.6a</td>
<td>503 (6.7)</td>
<td>2010</td>
<td>National HIV surveillance data (n = 7 490 cases)</td>
</tr>
<tr>
<td>Guatemala (55)</td>
<td>Maya, Garifuna, Xinca</td>
<td>60</td>
<td>3 510 (23.1)</td>
<td>2004–2010 (cumulative)</td>
<td>National HIV surveillance data (n = 15 195 cases)</td>
</tr>
<tr>
<td>Guatemala (54)</td>
<td>Maya:</td>
<td>60</td>
<td>179 (22.3)</td>
<td>2004–Oct 2009</td>
<td>National surveillance data (n = 814 HIV cases, age 5–19 years)</td>
</tr>
<tr>
<td></td>
<td>Garifuna:</td>
<td></td>
<td>5 (0.62)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Xinca:</td>
<td></td>
<td>2 (0.25)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Panama (56)</td>
<td>Ngäbe Buglé</td>
<td>NAb</td>
<td>85 (234.9/100 000)</td>
<td>2001–2008 (cumulative)</td>
<td>National HIV surveillance data crossed with 2004 census</td>
</tr>
</tbody>
</table>

Source: Prepared by the authors based on the study results and published data.

* (10).

b Centro Regional de Referencia, Información y Vigilancia.

c (61).

d NA: not applicable.

FIGURE 3. Data from 8 studies on prevalence of active syphilisa in indigenous peoples and Afro-descendants versus benchmark proxy,b Latin America, 2007–2014

<table>
<thead>
<tr>
<th>Geographic area (reference)</th>
<th>No. of HIV cases (reported cases)</th>
<th>Year(s) of data collection</th>
<th>Type of data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paraguay: 5 indigenous groups (n = 181 females)</td>
<td>2.8 (19.6)</td>
<td>2012</td>
<td>CRVIR HIV/AIDS surveillance (n = 2 544 cases)</td>
</tr>
<tr>
<td>Paraguay: 13 indigenous groups (n = 1 346)</td>
<td>3.4 (26.3)</td>
<td>2012</td>
<td>CRVIR HIV/AIDS surveillance (n = 139 cases)</td>
</tr>
<tr>
<td>Peru: Amazon, Chayahuita (n = 80)</td>
<td>0.3 (3.3)</td>
<td>2010</td>
<td>National HIV surveillance data (n = 7 490 cases)</td>
</tr>
<tr>
<td>Peru: Amazon, Chayahuita (n = 282)</td>
<td>0.3 (3.2)</td>
<td>2010</td>
<td>National HIV surveillance data (n = 15 195 cases)</td>
</tr>
<tr>
<td>Peru: Amazon, 6 indigenous groups (n = 956)</td>
<td>0.1 (1.0)</td>
<td>2009</td>
<td>National HIV surveillance data (n = 1619 HIV cases, 2 478 AIDS cases)</td>
</tr>
<tr>
<td>Peru: Amazon, Chayahuita (n = 733)</td>
<td>0.3 (3.1)</td>
<td>2009</td>
<td>National HIV surveillance data (n = 2544 cases)</td>
</tr>
<tr>
<td>Honduras: Garifuna (n = 608)</td>
<td>1.0 (2.1)</td>
<td>2010</td>
<td>National HIV surveillance data (n = 814 HIV cases, age 5–19 years)</td>
</tr>
<tr>
<td>Honduras: Garifuna (n = 817)</td>
<td>0.5 (1.3)</td>
<td>2010</td>
<td>National HIV surveillance data (n = 2 544 cases)</td>
</tr>
</tbody>
</table>

Source: Prepared by the authors based on the study results and published data.

* Based on non-treponemal tests combined with confirmatory treponemal tests.

b Comparison data extracted from Pan American Health Organization country reports using best proxy available in terms of date, population, and testing method (65).

c Non-probability sampling methods used.

d Probability sampling methods used.

e Based on WHO threshold (42).

population. Data on congenital syphilis were very limited. A Brazilian government report reporting 17 cases of congenital syphilis among indigenous peoples between 2000 and 2005 noted this as evidence of failure of prenatal service coverage of indigenous women (49). Out of concern that this low number of cases may reflect limited access to health services, a feasibility study for rapid syphilis testing was conducted in an indigenous Amazonian community (n = 282) and two cases of congenital syphilis were reported among the 19 cases of syphilis detected (63).

Burden of viral hepatitis in indigenous peoples and Afro-descendants

This review identified 25 documents containing data on VH in indigenous peoples and Afro-descendants from seven Latin American countries (Argentina, Brazil, Colombia, Guatemala, Mexico, Peru, and Venezuela). Of these 25 documents, two only reported data on hepatitis A (67, 68) and one only covered hepatitis G (GB virus C) (69) and were not further analyzed. Of the remaining 22 documents, 21 unique studies were

Rev Panam Salud Publica 43, 2019
identified, with 18 reporting data on prevalence of hepatitis B, six on hepatitis C, and four on hepatitis D.

Although tests for measuring the prevalence of hepatitis B varied, most studies reported both hepatitis B surface antigen (HBsAg), ranging from zero to 29.5%, and antibodies to hepatitis B core (anti-HBc), ranging from zero to 78%. Among the 18 studies reporting hepatitis B prevalence, six were conducted with Afro-Brazilians and the remaining 12 with indigenous groups. Figure 4 shows data from 16 of the 18 studies (27, 36, 70–83) that reported HBsAg prevalence in indigenous peoples and Afro-descendants in Argentina, Brazil, Colombia, Mexico, Peru, and Venezuela compared to Center for Disease Analysis (Lafayette, Colorado, USA) 2016 estimates of HBsAg for each country, and standardized definitions of endemicity (9). The two studies not included in Figure 4 were left out due to a small sample size (84) and a sample of children under 5 (85). All studies of Afro-Brazilian populations and nearly all studies of indigenous groups reported HBsAg prevalence values exceeding the level in the general population. Furthermore, this review identified studies reporting high endemicity (> 8%) in the following areas: Mato Grosso do Sul and Maranhão, Brazil (Afro-Brazilians) (73, 76, 78); Amazonas, Colombia (79); Nayarit, Mexico (Huichol) (81); and Amazonas and Zulia, Venezuela (Yanomami and Japreira, respectively) (82, 83). Areas of intermediate endemicity (2%–8%) were detected in the Amazon regions in Colombia (80), Peru (36), and Venezuela (82).


<table>
<thead>
<tr>
<th>Country</th>
<th>Region</th>
<th>Sample Size</th>
<th>Endemicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Argentina</td>
<td>4 indigenous groups (n = 561)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brazil</td>
<td>Paraná, Kaingang (n = 133)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brazil</td>
<td>Pará, Parakanã (n = 258)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brazil</td>
<td>Maranhão, Afro-Brazilian (n = 72)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brazil</td>
<td>Western Amazon, Afro-Brazilian (n = 2 656)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brazil</td>
<td>Goiás, Afro-Brazilian (n = 878)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brazil</td>
<td>Mato Grosso do Sul, Afro-Brazilian (n = 2 393)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brazil</td>
<td>Mato Grosso do Sul, Afro-Brazilian (n = 1 058)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brazil</td>
<td>Mato Grosso do Sul, Afro-Brazilian (n = 260)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colombia</td>
<td>Amazonas, 4 indigenous groups (n = 176)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colombia</td>
<td>Amazonas, Amerindians (n = 862)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colombia</td>
<td>Emberi Chami (n = 259)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mexico</td>
<td>Autlán, Jalisco, Nahua (n = 147)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mexico</td>
<td>Nayarit, Huichol (n = 159)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peru</td>
<td>Amazon, 6 indigenous groups (n = 899)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venezuela</td>
<td>Amazonas, Piaroa (n = 412)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venezuela</td>
<td>Amazonas, Yanomami (n = 231)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venezuela</td>
<td>Zulia, Japreira (n = 149)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: Prepared by the authors based on the study results and published data.

* (9).

** Non-random sampling methods used.

* Sampling methods not reported.

† Random sampling methods used.

‡ Afro-Brazilians accounted for 71.5% of population.

< 2% = Low endemicity  > 8% = High endemicity
The review found only one study containing data on hepatitis B in indigenous children under age 5 (85). The study found zero HBsAg prevalence and a low anti-HBe prevalence, suggesting low endemicity among young children in the Peruvian Amazon.

Six studies were found that reported the prevalence of antibodies to hepatitis C virus (anti-HCV), with a range of zero to 5.7% (three from Brazil (64, 71, 86) and one each from Colombia (79), Mexico (31), and Paraguay (84)). Overall, the prevalence of hepatitis C was low, apart from the studies in Colombia (prevalence of 5.7% in Amazonas) and Mexico (prevalence of 4.2% among indigenous peoples from 12 urban areas).

The review identified four studies reporting on the prevalence of antibodies to hepatitis D virus (anti-HDV) from Brazil (residents of Acre) (74); Colombia (two studies in indigenous groups from Amazonas) (79, 80); and Venezuela (indigenous peoples from Amazonas) (82). Overall anti-HDV prevalence ranged from 0.1% (in Venezuela) (82) to 8.3% (in Colombia) (79). In addition, three of these studies reported the prevalence of anti-HDV in HBsAg carriers, which ranged from 6.0% to 43.5%, clearly identifying a potential added risk of fulminant hepatitis and more severe progression to chronic liver disease in these populations due to HDV superinfection.

**DISCUSSION**

Although the observed burden of HIV was generally low, potential pockets of high prevalence (> 5%) were noted among the Garifuna (Honduras), some Warao communities (Venezuela), some Chayahuita communities (Peru), and some Wayuu females (Colombia). In addition, national surveillance data suggest proportionately higher HIV detection in Kuna Yala (Panama), and HIV-related mortality in Ngäbe Buglé (Panama) as well as Aymara (Chile). Furthermore, an elevated prevalence of active syphilis compared to national benchmarks was seen in all indigenous and Afro-descendant groups for which data were found, including high prevalence of active syphilis in some groups in Paraguay (two studies, including 18 indigenous tribes) and Peru (Chayahuita). Likewise, moderate to high endemicity of hepatitis B was noted among some indigenous populations in Brazil, Colombia, Mexico (Huichol), Peru, and Venezuela (Japera, Piraoa, and Yanomami), and among various Afro-descendant quilombola in Brazil.

The vulnerability to HIV and STIs is further highlighted by findings related to the knowledge, attitude, and practices studied in indigenous peoples and Afro-descendants in Latin America. Indigenous peoples have reported lower knowledge about HIV, its transmission, and preventive practices (87–89), and higher risk behavior, such as lower condom use (87, 90, 91), compared to national averages. In addition, indigenous and Afro-descendant females generally have exhibited lower knowledge about HIV transmission and prevention than men (27, 36, 38, 92, 93), and reported lower usage of condoms (29, 36, 44, 90), and higher levels of forced sex; whereas males have reported more multiple sexual partnerships (29, 30, 36, 87) and lower exposure to HIV tests (27, 30, 46).

Although a substantial amount of information was uncovered, many gaps were identified. Just six countries in Latin America were found to have case reporting or surveillance data on HIV and STIs disaggregated by ethnic origin (Bolivia, Brazil, Chile, Colombia, Guatemala, and Panama). Seroprevalence studies provide additional information, but no data were available for five countries (Costa Rica, Ecuador, El Salvador, Nicaragua, or Uruguay). Of more than 600 indigenous groups in Latin America (10), data were identified for only 66 named ethnic groups (some documents did not specify the names of the indigenous groups).

Additional data gaps were identified related to subgroups within indigenous peoples and Afro-descendants. Very little data were found on disease burden of HIV and syphilis among pregnant women and newborns (to monitor vertical transmission), which is concerning, considering the regional goal of eliminating mother-to-child transmission of HIV and syphilis (65).

Furthermore, no studies were found addressing the burden of HIV and STIs among indigenous or Afro-descendant MSM, sex workers, or drug users. Since the completion of this systematic review, one abstract was published on HIV in MSM in Guatemala that found HIV prevalence in indigenous MSM to be 4.8%, highlighting the need for further investigation with this population (94).

This systematic review also uncovered many inconsistencies in methodologies used to study indigenous or Afro-descendant populations. The criteria for determining ethnic origin varied widely (e.g., language spoken at home, residing in an indigenous area, provider assignment, and self-identification), although the recommended standard is self-identification (17). The sampling methods also varied, with many studies using convenience samples, given the challenges of studying remotely located populations. Heterogeneity was also found in the methods used to detect diseases, particularly for syphilis.

These findings provide important and timely information for Latin American countries as they begin implementing the new regional Policy on Ethnicity and Health (95), and the authors propose a number of recommendations. First, it is critical that the evidence of higher burden be confirmed and monitored with robust and more standardized surveillance methodologies. HIV, STI, and VH surveillance systems that consistently track the ethnicity of cases need to be developed and applied in all countries, including for vertical transmission. Given the potential shortcomings of case reporting systems in detecting epidemics in remote locations (with less access to health services, screening, and case notification), triangulation of data from a variety of sources should be considered for more accurate monitoring. Studies should apply an ethical approach to research using culturally sensitive strategies, engaging local communities, and ensuring participation of indigenous peoples and Afro-descendants, both females and males (96, 97). Furthermore, an effort should be made to identify health determinants, cultural factors, beliefs (e.g., traditional concepts of health and disease), and behaviors (e.g., MSM activity, sex work or transactional sex, alcohol and substance abuse, migration, etc.) within indigenous and Afro-descendant communities that elevate risk.

Second, HBV immunization programs need to be integrated with maternal and neonatal services, particularly in more remote areas, to address gaps in coverage of HBV birth dose vaccination (within the

---

*Resident of a quilombo (Brazilian hinterland settlement founded by people of African origin).
first 24 hours) that have been documented in the Peruvian and Colombian Amazon areas, possibly related to the low rate of facility-based delivery in certain indigenous communities (98). These services should include community-based outreach activities to administer the first dose of HBV vaccine to newborns delivered at home.

Third, there is an urgent need for health promotion and HIV/STI preventive interventions that take advantage of new technologies and are nondiscriminatory, culturally sensitive, and respectful of gender differences. In particular, syphilis screening programs should be prioritized, utilizing point-of-care rapid testing and timely penicillin treatment of individuals with a reactive treponemal test, as recommended by WHO (42). These interventions should be developed using an intercultural approach to health, promoting coexistence, respect, and mutual acceptance between the culture of the conventional health system and local cultures through collaboration with the community, the family, and social leaders (96, 97).

Finally, with improved data, evidence-based policies and service delivery models can also be designed and implemented using an intercultural approach that considers different contexts, priorities, and needs. This is critical for the elimination of service access barriers and to improve the health outcomes of indigenous peoples and Afro-descendants.

Limitations

The findings of this review are qualified by its limitations. First, to minimize data gaps, the review included as many data sources as possible, including government reports and conference abstracts, but this limited the quality of the data discovered. Furthermore, the methodological inconsistencies in the included studies limited data comparability. Also, many of the studies relied on non-probability sampling, increasing the possibility of bias. Finally, although this review highlights certain areas and ethnic groups with elevated disease prevalence, the paucity of available data has led to an underrepresentation of many geographic areas and ethnic groups in Latin America. Therefore, caution is advised in making any generalizations across ethnic groups or countries given the lack of data, the potential for bias in existing studies, the diverse populations studied, and the specific cultural contexts within which each indigenous and Afro-descendant group lives.

Conclusions

Although current evidence suggests an overall low burden of HIV, pockets of high prevalence in some of the populations studied, combined with elevated levels of syphilis and HBV, warrant improving national surveillance systems with systematic collection and analysis of ethnicity variables. Integrated biobehavioral studies employing robust methodologies and applying an ethical approach to research engaging in culturally sensitive strategies should be used to complement surveillance data. The responses to HIV, STIs, and VH in Latin America have rapidly progressed in the last decade, with increased participation of communities in policy action and governance, the expansion and decentralization of health services (including through community-based and peer-led services), and the availability of point-of-care diagnostics and simplified treatments. This new scenario offers opportunities to effectively address prevention and control of communicable diseases in indigenous peoples and Afro-descendants. Nevertheless, to eliminate health access barriers and improve the health outcomes, an intercultural approach to health promotion and service delivery is essential.

Acknowledgments. The authors wish to thank Adele Benzaken and Meritxell Sabidó for sharing their research results prior to publication to allow for their inclusion in this review.

Conflicts of interest. None.

Disclaimer. Authors hold sole responsibility for the views expressed in the manuscript, which may not necessarily reflect the opinion or policy of the RPSP/PAJPH or the Pan American Health Organization (PAHO).

REFERENCES


48. Vega J. Experiencia del CRVIR41 en


54. Dirección General de Regulación, Vigilancia y Control de la Salud, Programa Nacional de Prevención y Control de ITS, VIH, y SIDA (GT). Estudio antropológico multicentro sobre actitudes y prácticas de la población Maya sobre ITS, VIH y SIDA y el uso del condón, y estrategias de abordaje sobre sexualidad humana. Guatemala City: DGRVCs; 2010. Available from: http://www.pasca.org/content/estudios-de-vih-y-poblaciones-in-d%3C/3%3ADegenas


RESUMEN

Objetivo. Identificar y resumir la bibliografía existente sobre la carga de la infección por el VIH, las infecciones de transmisión sexual (ITS) y las hepatitis virales en las poblaciones indígenas y afrodescendientes en América Latina para proporcionar un panorama amplio de los datos cuantitativos disponibles y poner de relieve las brechas problemáticas que pudiera haber en los datos.

Métodos. Se hizo un examen sistemático de la bibliografía publicada y la bibliografía gris para encontrar documentos publicados en inglés, español o portugués con datos recogidos entre enero del 2000 y abril del 2016 sobre la carga de la infección por el VIH, las ITS y las hepatitis virales en las poblaciones indígenas y afrodescendientes en 17 países latinoamericanos.

Resultados. Se encontraron 62 documentos de 12 países. La prevalencia de la infección por el VIH fue generalmente baja (< 1%), pero se observaron focos de prevalencia alta (> 5%) en algunas comunidades indígenas en Venezuela (Warao) (9,6%), Perú (Chayahuita) (7,5%) y Colombia (las mujeres Wayuus) (7,0%). Se observó prevalencia alta de sífilis activa (> 5%) en algunas comunidades indígenas en Paraguay (11,6% y 9,7%) y Perú (Chayahuita) (6,3%). Se encontró endemicidad alta (> 8%) de la hepatitis B en algunos pueblos indígenas en México (Huichol) (9,4%) y Venezuela (Yanomami: 14,3%; Japreira: 29,5%) y en las poblaciones quilombola de afrodescendientes en Brasil (Frechal: 12,5%; Furnas do Dionísio: 8,4% en el 2008, 9,2% en el 2003).

Conclusiones. Las brechas en los datos existentes sobre la carga de la infección por el VIH, las ITS y las hepatitis virales en las poblaciones indígenas y afrodescendientes en América Latina destacan la necesidad de: 1) mejorar la vigilancia nacional mediante la recolección y el análisis sistemáticos de las variables de etnicidad y la ejecución de estudios bioconductuales integrados que utilicen metodologías sólidas y estrategias sensibles a diferencias entre las culturas; 2) elaborar una política de respuesta de alcance regional que considere las necesidades de las poblaciones indígenas y de afrodescendientes; y 3) aplicar un enfoque intercultural de la salud y de la prestación de servicios conexos para eliminar las barreras de acceso a la salud y mejorar los resultados en materia de salud para estas poblaciones.

Palabras clave. VIH; enfermedades de transmisión sexual; sífilis; hepatitis viral humana; salud de poblaciones indígenas; América Latina.
RESUMO

**Objetivo.** Identificar e sintetizar a literatura existente sobre a carga de HIV, infecções sexualmente transmissíveis (IST) e hepatite viral nos povos indígenas e afrodescendentes da América Latina para traçar um amplo panorama dos dados quantitativos disponíveis e destacar as lacunas problemáticas nos dados.

**Métodos.** Foi realizada uma revisão sistemática da literatura publicada e da literatura cinza para identificar documentos publicados em inglês, espanhol ou português com dados coletados entre janeiro de 2000 e abril de 2016 sobre a carga de HIV, IST e hepatite viral nos povos indígenas e afrodescendentes em 17 países latino-americanos.

**Resultados.** Sessenta e dois documentos de 12 países foram encontrados. A prevalência de HIV observada foi em geral baixa (<1%), com focos de alta prevalência (>5%) observados em comunidades indígenas da Venezuela (warao) (9,6%), Peru (chayahuita) (7,5%) e Colômbia (mulheres wayúu) (7,0%). Foi verificada uma alta prevalência de sífilis ativa (>5%) em comunidades indígenas no Paraguai (11,6% e 9,7%) e Peru (chayahuita) (6,3%). A alta endemicidade (>8%) de hepatite B foi observada em povos indígenas no México (huichol) (9,4%) e Venezuela (ianomâmi 14,3%; japrería 29,5%) e em comunidades negras quilombolas no Brasil (Frechal 12,5%; Furnas do Dionísio 8,4% em 2008 e 9,2% em 2003).

**Conclusões.** As lacunas nos dados existentes sobre a carga de HIV, IST e hepatite viral nos povos indígenas e afrodescendentes na América Latina destacam a necessidade de: melhorar a vigilância nacional com coleta sistemática e análise de variáveis de etnicidade e realizar estudos integrados de análise biocomportamental com o uso de metodologias robustas e estratégias sensíveis à diversidade cultural; desenvolver uma política de resposta regional que considere as necessidades dos povos indígenas e afrodescendentes; e implementar um enfoque intercultural à saúde e prestação de serviços para derrubar as barreiras de acesso à saúde e melhorar os resultados de saúde nestas populações.

**Palavras-chave** HIV; doenças sexualmente transmissíveis; sífilis; hepatite viral humana; saúde de populações indígenas; América Latina.